C

ould changing up regulatory requirements for Alzheimer’s drugs help give desperate patients new options for treatment?

A group of researchers and patient advocates think so. They authored a paper that argues that the Food and Drug Administration should evaluate Alzheimer’s drugs for efficacy in either cognition or function — but not both.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Obviously Klunk never worked in pharma. 30 years of experience has taught me that getting marginally efficacious drugs approved, then charging obscenely high prices before it is concluded that your drug is a dud is a good business model, because everybody who made their six figure bonuses along the way will be long gone by the time the poo hits the fan.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.